ItalyItaly

“It's Time to Invest in Biotech in Italy”

06.08.2004

On July 5, 2004 the annual general assembly of Assobiotec - Italian Association for the Development of Biotechnology - took place in Milan, hosted by the stock exchange. Main focus of the public part was on the growing opportunities and attractiveness offered by the arising national bioindustry for private investment.

The newly appointed president of Assobiotec, Roberto Gradnik, CEO of Serono Italia, underlines the rapid growth of the Italian biotech industry in the very last years: “However, so far the sector appears to be focused only on medical applications, while the country's knowledge resources in green and white applications still lack adequate entrepreneurial exploitation. Anyway, the existing core of new biotech companies shows a very good score in terms of product pipeline, with 16 new drugs in pre-clinical or clinical development, 6 of which with orphan drug status,” he states.
Is Italy's biotech at the turning point towards a strategic development? Asso-biotec's view is optimistic. Gradnik says: “The first step must be the creation of a suitable general context, in order to catch up the delay in terms of critical mass with respect to the major international competitors. In the European context, the UK, France and Germany already showed their determination in supporting biotech's development with specific incentives. So far, Italy hasn't enjoyed a similar framework, and the existing core of dedicated companies emerged without any support, through a harsh selection of scientific excellence peaks and entrepreneurial capabilities. But in a favourable environment the potential for the creation of new dedicated companies could be by far greater”.
Assobiotec's assembly called for a number of specific measures and provisions by the national institutions which are highly needed in order to attract private investments in the biotech industry. Among these, a clear recognition of innovation as a strategic priority and a positive attitude towards the value and protection of knowledge-based “goods” (e.g. a proper implementation of the EU directive on biotech patents); furthermore, the EU-derived rules should be enforced with full respect of the notion of single EU market. Last but not least, there should be a system of fiscal incentives for high-tech enterprises in line with the leading countries, and a steady commitment into a permanent and full enforcement of the existing measures in favour of the development of industrial research and innovation.
Contact
Assobiotec
Via Giovanni da Procida 11
20149 Milano, Italy
Tel.: +39-2-34565308
Fax: +39-2-34565284
eMail: media.assobiotec@federchimica.it
Web:www.assobiotec.it

ItalyItaly

07.03.2012

Toscana Biomarkers S.r.l has entered the market for biomarkers with its first diagnostic kit. In late January, the company from Siena signed a licence agreement with DIESSE Ricerche S.r.l, based in Genoa. DIESSE will produce and...

ItalyItaly

07.03.2012

Italian researchers have reprogrammed neonatal cardiomyocytes into iPSCs that can re-differentiate toward CMs more efficiently than either cardiac fibroblast-derived iPS cells or even ES cells. (Cell Death Differ.,...

ItalyItaly

09.01.2012

Rome – A cold virus isolated from chimpanzees might work as an vector for human vaccines. Adenoviruses are principally suitable as vectors for vaccines for their ability to induce strong immune responses. But as most humans have...

ItalyItaly

16.12.2011

Milan/Turku – Italian drug developer Newron SpA has had a roller-coaster ride in the last few months. First Merck Serono decided to drop its stake in the company’s Parkinson’s Disease candidate salfinamide, and returned the...

ItalyItaly

15.12.2011

Genoa/Irvine – Researchers from the universities at Genoa and Irvine (US) have patented a new compound that blocks removal of the endo­cannabinoid painkiller anandamide from the synaptic space by a selective transport system....

ItalyItaly

01.10.2011

Parma/Baranzate – Chiesi Farmaceutici Spa has said it will lengthen its long-term collaboration with NiKem Research, which is focused on developing treatments within the respiratory therapeutic area. The two drug developers have...

ItalyItaly

01.10.2011

Milan/Turku – Biotie Therapies ASA’s announcement that it had signed an agreement to acquire Newron Pharma­ceuticals S.p.A. for €45m is both good and bad news for the Italian biotechnology sector. While Italy is losing one of its...

ItalyItaly

19.08.2011

Como – Shares in Gentium SpA lost about a third of their value on Thursday after The Italian biopharmaceutical company withdrew a marketing application for its drug Defibrotide being used against complications related to stem...

ItalyItaly

01.08.2011

Milan/London – Italy’s MolMed SpA has signed a deal with UK-based pharmaceutical giant GlaxoSmithKline to develop a production process for a gene therapy against the rare ‘bubble boy disease’. Over the next two years, GSK will...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-italy/article/its-time-to-invest-in-biotech-in-italy.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • 4SC0.97 EUR15.48%
  • THERAMETRICS0.08 CHF14.29%
  • CYTOS0.17 CHF13.33%

FLOP

  • MOLOGEN6.60 EUR-13.16%
  • WILEX2.15 EUR-1.83%
  • ADDEX3.40 CHF-1.16%

TOP

  • BIOFRONTERA2.92 EUR32.7%
  • BB BIOTECH157.00 EUR7.2%
  • ADDEX3.40 CHF6.6%

FLOP

  • PAION2.22 EUR-31.9%
  • CYTOS0.17 CHF-19.0%
  • MAGFORCE5.95 EUR-15.6%

TOP

  • SANTHERA84.30 CHF2248.2%
  • CO.DON2.84 EUR202.1%
  • PAION2.22 EUR161.2%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 22.10.2014


Current issue

All issues

Product of the week

Products